SCHEMBL146422

SCHEMBL146422

C=C[C@@]1(C)CC[C@@H]2[C@@]3(C)CCC[C@@](C)(CO)[C@@H]3CC[C@@]2(C)O1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.45
HSD11B2 P80365 1/20 0.45
LMNA P02545 2/20 0.41
CYP3A4 P08684 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NR1H3 Q13133 1/20 0.40
CDC25A P30304 4/20 0.40
CDC25B P30305 4/20 0.40
BCHE P06276 3/20 0.38
ACHE P22303 2/20 0.38
PTPN1 P18031 1/20 0.37
NR1H4 Q96RI1 1/20 0.36
PLA2G1B P04054 1/20 0.35
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15588772 1.00 HSD11B1 (0.45) HSD11B1HSD11B2LMNACYP3A4SMN1; SMN2
SCHEMBL16502918 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL16982582 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL3973400 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL16984766 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL3967644 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL16984745 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL20086741 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL18197939 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15
SCHEMBL29799288 0.82 ALDH1A1 (0.48) CYP3A4PTPN1NR1H4ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090232913-A1 Composition for the Control of Cholesterol Levels VANADIS BIOSCIENCE LTD. (NZ) 2009-09-17 US claimed
US-20090074895-A1 COMPOSITION AND USES THEREOF VANADIS BIOSCIENCE LTD (NZ) 2009-03-19 US claimed
WO-2006116814-A1 COMPOSITION AND USES THEREOF VANADIS BIOSCIENCE LTD (NZ) 2006-11-09 WO claimed
WO-2006116815-A1 COMPOSITION FOR THE CONTROL OF CHOLESTEROL LEVELS VANADIS BIOSCIENCE LTD (NZ) 2006-11-09 WO claimed
EP-3714699-B1 STEVIA EXTRACT CONTAINING SELECTED STEVIOL GLYCOSIDES AS FLAVOR, SALTY AND SWEETNESS PROFILE MODIFIER PURECIRCLE USA INC (US) 2024-12-18 EP disclosed
US-12011017-B2 Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier PURECIRCLE USA INC. (US) 2024-06-18 US disclosed
US-11957756-B2 Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier PURECIRCLE SDN BHD (MY) 2024-04-16 US disclosed
EP-3272232-B1 REBAUDIOSIDE A AND STEVIOLBIOSIDE COMPOSITIONS SWEET GREEN FIELDS INTERNATIONAL CO LTD (HK) 2024-01-03 EP disclosed
EP-3003058-B2 STEVIA EXTRACT CONTAINING SELECTED STEVIOL GLYCOSIDES AS FLAVOR, SALTY AND SWEETNESS PROFILE MODIFIER PURECIRCLE USA INC (US) 2023-06-28 EP disclosed
US-11202462-B2 Rebaudioside A and stevioside compositions SWEET GREEN FIELDS INTERNATIONAL CO., LIMITED (HK) 2021-12-21 US disclosed
US-20210186070-A1 STEVIA EXTRACT CONTAINING SELECTED STEVIOL GLYCOSIDES AS FLAVOR, SALTY AND SWEETNESS PROFILE MODIFIER PURECIRCLE USA INC. 2021-06-24 US disclosed
US-10952458-B2 Stevia extract containing selected steviol glycosides as flavor, salty and sweetness profile modifier PURECIRCLE USA INC (US) 2021-03-23 US disclosed
US-20120058247-A1 REBAUDIOSIDE A AND STEVIOSIDE COMPOSITIONS Zhejiang Green World Bio-Tech Engineering Co., Ltd . (CN) 2012-03-08 US disclosed
WO-2012025828-A2 SUPERFINE POWDERED STEVIA E.P.C. (BEIJING) PLANT PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2012-03-01 WO disclosed
CN-102318484-A Mechanical field sowing method for stevia rebaudiana ALAER CITY XINTANG HIGH TECH CO LTD 2012-01-18 CN disclosed
US-20100112101-A1 BIO-AVAILABILITY/BIO-EFFICACY ENHANCING ACTIVITY OF STEVIA REBAUDIANA AND EXTRACTS AND FRACTIONS AND COMPOUNDS THEREOF LAILA IMPEX (IN) 2010-05-06 US disclosed
US-20090232913-A1 Composition for the Control of Cholesterol Levels VANADIS BIOSCIENCE LTD. (NZ) 2009-09-17 US disclosed
US-20090074895-A1 COMPOSITION AND USES THEREOF VANADIS BIOSCIENCE LTD (NZ) 2009-03-19 US disclosed
WO-2006116814-A1 COMPOSITION AND USES THEREOF VANADIS BIOSCIENCE LTD (NZ) 2006-11-09 WO disclosed
WO-2006116815-A1 COMPOSITION FOR THE CONTROL OF CHOLESTEROL LEVELS VANADIS BIOSCIENCE LTD (NZ) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090232913-A1 Composition for the Control of Cholesterol Levels CETP, HMGCR, CYP46A1 HSD11B1 46/4885HSD11B2 53/4885LMNA 2634/4885
US-20090074895-A1 COMPOSITION AND USES THEREOF SLC5A2, SLC5A1, SLC10A1 HSD11B1 73/4885HSD11B2 57/4885LMNA 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.